Clinical Trial Update: A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tocilizumab's effect on markers of atherogenic risk in patients with moderate-to-severe rheumatoid arthritis; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2012-11-14